Home/Pipeline/monzosertib

monzosertib

Oncology (unspecified)

PreclinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Preclinical

Status

Active

Company

Carna Biosciences

About Carna Biosciences

Carna Biosciences is a dual-strategy Japanese biotech with a core focus on developing proprietary kinase inhibitors for oncology and hematology, while also generating revenue through a portfolio of kinase-focused research products and discovery services. Its lead clinical assets include docirbrutinib, a next-generation BTK inhibitor for B-cell malignancies, and monzosertib, a preclinical compound. The company is publicly traded, leveraging its deep kinase expertise to build a pipeline and support external R&D efforts.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active